Recent Posts

Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes

Recently co-authored: Real-world outcomes (~50,000 eyes) of anti-VEGF therapy for AMD – only 1 letter gained at 1 year, meaningfully worse than clinical trials. Download: https://lnkd.in/efPCAD5 https://www.sciencedirect.com/science/article/pii/S2468653019302805?via%3Dihub Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World […]

The 2017 U.S. FDA approval of the first gene therapy for a genetic disease launc…

The 2017 U.S. FDA approval of the first gene therapy for a genetic disease launched a promising new cycle of innovation in ophthalmic therapies…. https://www.youtube.com/watch?v=FNUUnJgWHUY&t= Watch the Advancements in Genetic and Regenerative Therapies panel at Ophthalmology Innovation Summit @ ASRS 2019. REGISTER for our next […]

Retina Today – Seeking Therapies for Stargardt Macular Dystrophy


Just published a brief review on Stargardt Macular Dystrophy, the most common inherited macular degeneration…Clinical trials are evaluating visual cycle modulation, complement inhibition, gene therapy, and subretinal transplantation of stem cell–derived RPE cells.

PDF for download: https://lnkd.in/efZ9dTp

Retina Today – Seeking Therapies for Stargardt Macular Dystrophy

Clinical research teams are working toward a treatment for Stargardt disease. How far have they come?


Return to main website.

Innovative therapies for neovascular age-related macular degeneration

Just co-authored a comprehensive review, “Innovative Therapies for Neovascular Age-Related Macular Degeneration”… https://lnkd.in/e4P5Z3W Innovative therapies for neovascular age-related macular degeneration (2019). Innovative therapies for neovascular age-related macular degeneration. Expert Opinion on Pharmacotherapy. Ahead of Print. Return to main website.

Ophthalmology Management – Introduction to gene therapy

Recently authored “Introduction to Gene Therapy”, a brief primer, in Ophthalmology Management’s “Revolution in Retina” issue… Ophthalmology Management – Introduction to gene therapy New gene therapy research could result in treatments for chronic disorders of the retina, including neovascular AMD, geographic atrophy, uveitis and more. […]

Recently co-authored a paper on retinitis pigmentosa and associated vascular dys…


Recently co-authored a paper on retinitis pigmentosa and associated vascular dysfunction…https://lnkd.in/ecP8XRd #




Return to main website.

Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy

Recently co-authored the first study to report HRQL weights (utilities) for health states in inherited retinal dystrophy patients, corroborating substantial impact of vision loss on HRQL. https://lnkd.in/e9mcYJ2 Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene […]

Retinal Physician – “Real-World” Outcomes of Anti-VEGF Therapy in Neovascular AMD in the United States

In our “real world” study of 49,485 “wet” AMD patient-eyes treated with anti-VEGF agents, visual acuity improved by only 1 letter at 1 year! Outcomes fall far short of randomized clinical trial results. New therapies are needed. Retinal Physician – “Real-World” Outcomes of Anti-VEGF Therapy […]

Just published a brief review of recent research on real-world outcomes of anti-…


Just published a brief review of recent research on real-world outcomes of anti-VEGF therapy for diabetic macular edema, which are meaningfully worse than in clinical trials – https://lnkd.in/ebtVhXK




Return to main website.

Retinal Physician – Gene Therapy Implications for Retina Specialists

Just published, “Gene Therapy Implications for Retina Specialists: Evolving endpoints, novel orphan disease treatment paradigms, and the dawn of precision medicine.” The approval and launch of Spark’s LUXTURNA (voretigene neparvovec-ryzl), the first FDA-approved gene therapy for a genetic disease, introduces novel paradigms to clinical practice, […]